Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Peter Parker

MET-EGFR Dimerization in Lung Adenocarcinoma Is Dependent on EGFR Mtations and Altered by MET Kinase Inhibition

PLoS ONE

Multidisciplinary

2017

English

Editor's Note

Quality Engineering

Industrial

Risk

Manufacturing Engineering

English

Related publications

Acquired Resistance Mechanisms to Combination Met-Tki/Egfr-Tki Exposure in Met-Amplified EGFR-TKI–Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation

Molecular Cancer Therapeutics

Cancer Research

Oncology

2016

English

P3.cr-09 MET-UBE2H Fusion as a Novel Mechanism of Acquired EGFR Resistance in Lung Adenocarcinoma" With "MET Fusion as a Novel Mechanism of Acquired EGFR Resistance in Lung Adenocarcinoma

Journal of Thoracic Oncology

English

A Case of EGFR Mutant Lung Adenocarcinoma That Acquired Resistance to EGFR-tyrosine Kinase Inhibitors With MET Amplification and Epithelial-To-Mesenchymal Transition

OncoTargets and Therapy

Oncology

Pharmacology

2015

English

MET-UBE2H Fusion as a Novel Mechanism of Acquired EGFR Resistance in Lung Adenocarcinoma

Journal of Thoracic Oncology

English

P1.13-20 MET Protein Expression and Activation During Targeted Therapy in EGFR Mutated Lung Adenocarcinoma

Journal of Thoracic Oncology

English

P2.13-21 MET Addiction Can Be Circumvented Through EGFR Inhibition via AXL in MET-Amplified Primary Resistant EGFR-Mutant NSCLCX.

Journal of Thoracic Oncology

English

Combination of Crizotinib and Osimertinib or Erlotinib Might Overcome MET-Mediated Resistance to EGFR Tyrosine Kinase Inhibitor in EGFR-Mutated Adenocarcinoma

Journal of Thoracic Oncology

English

Triple Inhibition of EGFR, Met, and VEGF Suppresses Regrowth of HGF-Triggered, Erlotinib-Resistant Lung Cancer Harboring an EGFR Mutation

Journal of Thoracic Oncology

English

The Persistent Promise of Combining HGF/MET and EGFR Inhibition in Non-Small Cell Lung Cancer

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Peter Parker

MET-EGFR Dimerization in Lung Adenocarcinoma Is Dependent on EGFR Mtations and Altered by MET Kinase Inhibition

Editor's Note

Related publications

Acquired Resistance Mechanisms to Combination Met-Tki/Egfr-Tki Exposure in Met-Amplified EGFR-TKI–Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation

P3.cr-09 MET-UBE2H Fusion as a Novel Mechanism of Acquired EGFR Resistance in Lung Adenocarcinoma" With "MET Fusion as a Novel Mechanism of Acquired EGFR Resistance in Lung Adenocarcinoma

A Case of EGFR Mutant Lung Adenocarcinoma That Acquired Resistance to EGFR-tyrosine Kinase Inhibitors With MET Amplification and Epithelial-To-Mesenchymal Transition

MET-UBE2H Fusion as a Novel Mechanism of Acquired EGFR Resistance in Lung Adenocarcinoma

P1.13-20 MET Protein Expression and Activation During Targeted Therapy in EGFR Mutated Lung Adenocarcinoma

P2.13-21 MET Addiction Can Be Circumvented Through EGFR Inhibition via AXL in MET-Amplified Primary Resistant EGFR-Mutant NSCLCX.

Combination of Crizotinib and Osimertinib or Erlotinib Might Overcome MET-Mediated Resistance to EGFR Tyrosine Kinase Inhibitor in EGFR-Mutated Adenocarcinoma

Triple Inhibition of EGFR, Met, and VEGF Suppresses Regrowth of HGF-Triggered, Erlotinib-Resistant Lung Cancer Harboring an EGFR Mutation

The Persistent Promise of Combining HGF/MET and EGFR Inhibition in Non-Small Cell Lung Cancer